Drug Approval | December 12, 2024
Briefs: Alembic Pharmaceuticals and Veerhealth Care
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
For people with relapsed or refractory diffuse large B-cell lymphoma
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
